Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Smart Eye in conjunction with a rights issue of MSEK 324.
Mandate

Vinge has advised Smart Eye in conjunction with a rights issue of MSEK 324.

February 20, 2023 Capital Markets and Public M&A

Vinge has advised Smart Eye Aktiebolag (First North Growth Market) in connection with its fully secured rights issue which provided Smart Eye with MSEK 324 before transaction costs. The issue was fully subscribed and no guarantee commitments had to be utilised.

Vinge's team primarily mainly of Anders Strid, Oscar Lunde (project manager), Amelia Rihs, Fredrik Löwenclou and corporate assistant Daniela Maniscalchi. Carnegie acted as financial advisor to Smart Eye.

Read more here

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026